J. Heymach

Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D mutated non-small cell lung cancer.

M. Meyerson, P. Jänne, A. Cherniack, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features

P. A. Futreal, P. Scheet, I. Wistuba, 2020, Nature Communications.

Immunogenomic profiling of lung adenocarcinoma reveals high-grade growth patterns are associated with an immunogenic tumor microenvironment

Jianhua, P. A. Futreal, P. Scheet, 2022, medRxiv.

EP02.04-005 Phase II NAUTIKA1 Study of Targeted Therapies in Stage II-III NSCLC: Preliminary Data of Neoadjuvant Alectinib for ALK+ NSCLC

J. Chaft, B. Sepesi, E. Toloza, 2022, Journal of Thoracic Oncology.

Randomized phase II study of vandetanib (VAN) alone or in combination with carboplatin and paclitaxel (CP) as first-line treatment for advanced non-small cell lung cancer (NSCLC)

R. Herbst, L. Paz-Ares, M. Sebastian, 2007 .

Preliminary phase II safety evaluation of ZD6474, in combination with carboplatin and paclitaxel, as 1st-line treatment in patients with NSCLC

R. Herbst, J. Heymach, D. Prager, 2005 .